| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.06 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.06 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.06 |